证券代码：002019 证券简称：亿帆医药 公告编号：2024-059 亿帆医药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2024年11月21日收到国家药品监督管理局核准签发的甲硫酸新斯的 明注射液《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 9、药品批准文号有效期：至2029年11月14日 1、药品名称：甲硫酸新斯的明注射液 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品3类 5、规格：1ml:0.5mg、2ml:1mg、4ml:2mg 6、药品受理号：CYHS2301543、CYHS2301544、CYHS2301545 7、证书编号：2024S02733、2024S02734、2024S02735 8、药品批准文号：国药准字H20249339、国药准字H20249340、国药准字 H20249341 10、上市许可持有人：合肥亿帆生物制药有限公司 11、生产企业：合肥亿帆生物制药 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2024-060 亿帆医药股份有限公司 关于在下属子公司之间调剂担保额度及为全资子公司提供担保 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 本次担保被担保对象上海亿帆为公司全资子公司，其最近一期资产负债率超 70％，敬请投资者关注担保风险。 一、担保额度调剂情况 亿帆医药股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开的第 八届董事会第十一次会议及 2024 年 5 月 17 日召开的 2023 年年度股东大会，均 审议通过了《关于公司及控股公司向金融机构申请授信额度及公司合并报表范围 内担保额度的议案》，同意公司及控股公司向各家金融机构申请总额度不超过人 民币 580,000 万元（或等值外币）的综合授信融资，申请纳入公司合并报表范围 内的公司（含本次预计担保批准期间内新设立或收购的全资和控股子公司）相互 提供担保，担保额度合计不超过人民币 530,000 万元（或等值外币），其中：对 合并范围内资产负债率低于 70%的公司提供担保总额度 300,000 万 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002019 证券简称：亿帆医药 公告编号：2024-058 一、担保情况概述 亿帆医药股份有限公司 （一）担保基本情况 亿帆医药股份有限公司（以下简称"公司"）因全资子公司合肥亿帆生物制 药有限公司（以下简称"亿帆制药"）业务发展需要，于近日与中国银行股份有 限公司合肥庐阳支行（以下简称"中国银行庐阳支行"）签订《保证合同》，同 意为亿帆制药向中国银行庐阳支行形成的债务提供连带责任保证，担保金额为人 民币5,000万元。 关于为全资子公司提供担保的进展公告 （二）担保的审议情况 公司于2024年4月18日召开的第八届董事会第十一次会议及2024年5月17日 召开的2023年年度股东大会，均审议通过了《关于公司及控股公司向金融机构申 请授信额度及公司合并报表范围内担保额度的议案》，本次担保事项涉及的金额 及合同签署时间在公司第八届董事会第十一次会议及2023年年度股东大会审议 批准范围内，无需再次履行审议程序。 二、被担保人基本情况 公司名称：合肥亿帆生物制药有限公司 注册时间：2016年5月23日 注 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][15] Core Views - The company reported a significant increase in revenue and profit for the first three quarters of 2024, with total revenue reaching 3.858 billion yuan, a year-on-year growth of 31.67%, and net profit attributable to shareholders of 366 million yuan, a year-on-year increase of 149.50% [3] - The growth in self-developed and introduced pharmaceutical products has been substantial, contributing to the impressive profit growth, alongside increased government subsidies and revenue from drug agency rights transfer [3][4] - The company has optimized its expense ratios significantly, with sales expense ratio at 24.93%, management expense ratio at 7.25%, and financial expense ratio at 1.29% [4] Financial Performance Summary - For the first three quarters of 2024, the company achieved a net cash flow from operating activities of 430 million yuan, a year-on-year increase of 37.27% [3] - The company expects revenue for 2024 to be 5.227 billion yuan, with a year-on-year growth of 28.49%, and net profit attributable to shareholders to be 524 million yuan, reflecting a growth of 195.0% [5][11] - The projected earnings per share (EPS) for 2024 is 0.43 yuan, with corresponding price-to-earnings (PE) ratios of 29.73 for 2024, 19.96 for 2025, and 16.76 for 2026 [5][11] Product Development and Market Expansion - The company has accelerated the global rollout of its product Yilishu, which has received approvals in multiple countries and regions, including the EU and the US [4] - The company continues to advance its research and development efforts in both chemical and traditional Chinese medicine, with several new products receiving registration certificates [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next 6 months [11]. Core Views - The company reported a revenue of 3.86 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 31.7%, and a net profit of 370 million yuan, up 149.5% year-on-year [1]. - The company has successfully launched its innovative drug Ryzneuta (亿立舒) in Germany, marking a significant step in its international expansion, with plans for further launches in the US and EU [2]. - The company is experiencing rapid growth in its research and development, focusing on breakthroughs in blood cancers, rare diseases, and solid tumors, which is expected to support long-term growth [3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 1.23 billion yuan, a 24.3% increase year-on-year, and a net profit of 110 million yuan, up 196.3% year-on-year [1]. - The gross margin and net margin for Q3 2024 were reported at 47.4% and 7.8%, respectively, with a significant improvement in net margin [1]. - The company has seven products with sales exceeding 100 million yuan, with key products contributing significantly to revenue growth [1]. Research and Development - The company has made substantial progress in R&D, with discussions with regulatory bodies regarding clinical trials for new treatments, including F-652 for acute liver failure and severe alcoholic hepatitis [3]. - The company has received registration certificates for five generic drugs and is actively pursuing further product registrations [3]. Future Projections - The report forecasts revenue growth rates of 35%, 19%, and 20% for 2024, 2025, and 2026, respectively, with net profit growth rates of 200%, 32%, and 31% for the same years [5]. - Earnings per share (EPS) are projected to be 0.45 yuan, 0.59 yuan, and 0.78 yuan for 2024, 2025, and 2026, respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company has demonstrated strong revenue growth, with total revenue reaching 3.858 billion yuan in the first three quarters of 2024, a year-on-year increase of 31.67%. The net profit attributable to shareholders was 366 million yuan, up 149.5% year-on-year [2]. - The innovative drug Yili Shou has made significant progress in its global rollout, with the first shipment to Germany completed on October 30, 2024. This drug is expected to drive substantial sales growth in the European market [4]. - The company's focus on a "big product" strategy has led to continued revenue growth in its pharmaceutical segment, with seven domestic products achieving sales exceeding 100 million yuan [2]. Financial Performance - For the first three quarters of 2024, the gross profit margin was 47.65%, a decrease of 2.95 percentage points year-on-year, primarily due to increased costs from the amortization of intangible assets related to self-developed pharmaceutical products [3]. - The company reported a sales expense ratio of 24.93%, a decrease of 1.7 percentage points year-on-year, and a management expense ratio of 7.25%, down 2.24 percentage points year-on-year [3]. - The forecast for net profit attributable to shareholders for 2024-2026 is 518 million, 727 million, and 968 million yuan, respectively, with growth rates of 194%, 40%, and 33% [5]. Market Position and Future Outlook - The global market for the drug Yili Shou is estimated at 7 billion USD, with peak sales potential exceeding 5 billion yuan [4]. - The company is expected to benefit from its innovative pipeline and the ongoing implementation of its "big single product" strategy, anticipating a performance turnaround in 2024 [5].

Investment Rating - The investment rating for the company is "Buy" with a 6-month target price maintained at 12.56 CNY [2][4]. Core Views - The company achieved a revenue of 3.858 billion CNY in the first three quarters of 2024, representing a year-on-year growth of 31.7%. The net profit attributable to shareholders reached 366 million CNY, up 150% year-on-year [2]. - The company’s product, Yilishu (F-627), has completed its first overseas shipment, marking a significant step in its international commercialization [3]. - The company has seen strong growth in its exclusive products, with several innovative drugs contributing significantly to its performance [4]. Financial Performance Summary - For the first three quarters of 2024, the company reported a revenue of 3.858 billion CNY, a 31.7% increase year-on-year, and a net profit of 366 million CNY, which is a 150% increase year-on-year [2]. - In Q3 2024, the company generated a revenue of 1.226 billion CNY, reflecting a 24.3% year-on-year growth, with a net profit of 113 million CNY, up 196% year-on-year [2]. - The company’s revenue forecast for 2024-2026 has been adjusted downwards to 5.201 billion CNY, 6.403 billion CNY, and 7.107 billion CNY respectively [4]. Product Development and Market Expansion - Yilishu (F-627) is the first third-generation white blood cell booster approved in China and has successfully entered the national medical insurance directory, with significant sales growth expected in 2024 [3]. - The company’s partner, Tianliyuanhe, has released early efficacy data for its investigational product A-319 in treating systemic lupus erythematosus (SLE), showing rapid effects [12]. - A-319 has demonstrated significant improvements in SLEDAI-2K scores among patients, indicating its potential in the market [12]. Market Position and Competitive Landscape - The company has seven products with sales exceeding 100 million CNY, with innovative drugs like Yilishu being the main contributors to revenue growth [4]. - The competitive landscape for A-319 is highlighted by recent global interest in CD3&CD19 T cell engagers, indicating a strong market potential for the company’s offerings [11][19]. Financial Projections - The company’s projected revenues for 2024, 2025, and 2026 are 5.201 billion CNY, 6.403 billion CNY, and 7.107 billion CNY respectively, with corresponding net profits of 500 million CNY, 720 million CNY, and 910 million CNY [8][21]. - The company’s earnings per share (EPS) is expected to improve from -0.45 CNY in 2023 to 0.41 CNY in 2024, reflecting a positive trend in profitability [21].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 3.858 billion yuan in Q3 2024, representing a year-on-year increase of 31.67%, with a net profit attributable to shareholders of 366 million yuan, up 149.50% year-on-year [1] - The company is accelerating its globalization efforts, with the launch of its innovative drug Ryzneuta® in the European market [1] - The company has shown significant improvement in operational efficiency, leading to a reduction in expense ratios despite a slight decline in gross margin [1] Financial Performance Summary - Revenue for 2024 is projected to be 51.1 billion yuan, with year-on-year growth rates of 25.6%, 18.9%, and 7.1% for 2025 and 2026 respectively [2][5] - The net profit attributable to shareholders is expected to reach 5.5 billion yuan in 2024, with a staggering year-on-year growth of 199.6% [2][5] - The gross margin is forecasted to improve from 47.8% in 2023 to 52.8% by 2026 [2][5] Cash Flow and Balance Sheet Summary - Operating cash flow is expected to increase significantly, reaching 1.317 billion yuan by 2026 [3] - Total assets are projected to grow from 115 billion yuan in 2023 to 136.48 billion yuan in 2026 [4] - The company’s total liabilities are expected to remain stable, with a slight increase from 3.245 billion yuan in 2023 to 3.702 billion yuan in 2026 [4] Key Financial Ratios - The company’s return on equity (ROE) is projected to improve from -6.7% in 2023 to 9.8% by 2026 [5] - The price-to-earnings (P/E) ratio is expected to decrease from 23.95 in 2024 to 13.27 by 2026, indicating a more attractive valuation over time [5] - The debt-to-asset ratio is projected to increase slightly from 28.2% in 2023 to 30.5% in 2024, before stabilizing [5]

Investment Rating - The report maintains a "Buy" investment rating for Yifan Pharmaceutical (002019) with a target price based on the last closing price of 11.96 [1][4]. Core Insights - Q3 performance met expectations with a significant improvement in net profit margin. The company reported a revenue of 12.26 billion yuan for Q3, representing a year-over-year increase of 24.32%, and a net profit of 1.13 billion yuan, reflecting a year-over-year growth of 196.33% [1][4]. - The growth in performance is attributed to increased revenue from new and existing pharmaceutical products, as well as higher government subsidies and income from transferring drug agency rights [1][4]. - The company has effectively controlled sales expenses, leading to a noticeable improvement in net profit margin. The gross margin for Q1-Q3 2024 was 47.65%, while the net margin was 7.98%, showing an increase of 4.53 percentage points year-over-year [1][4]. - The global commercialization of innovative drugs is actively progressing, which is expected to drive future performance. The drug Yilishu has been approved for sale in China, the US, and the EU, with anticipated sales exceeding 5 billion yuan in 2024 [1][4]. Financial Summary - For the first three quarters of 2024, the company achieved a total revenue of 38.58 billion yuan, a year-over-year increase of 31.67%, and a net profit of 3.66 billion yuan, up 149.50% year-over-year [1][4]. - The projected revenues for 2024-2026 are 53.09 billion yuan, 64.17 billion yuan, and 74.23 billion yuan, with respective year-over-year growth rates of 30.51%, 20.86%, and 15.68% [4][6]. - The expected net profits for the same period are 5.06 billion yuan, 6.77 billion yuan, and 8.60 billion yuan, with year-over-year growth rates of 191.88%, 33.77%, and 26.95% [4][6].

证券时报e公司讯，据亿帆医药消息，控股子公司亿一生物有限公司（"亿一生物"）于德国时间10月30 日成功完成了创新药物Ryzneuta®在德国市场的首批发货。 Ryzneuta®是首个在中美欧获批源于中国的第三代G-CSF，是目前国内唯一在全球申请上市的"用于预防 和治疗肿瘤患者在接受抗癌药物后出现的中性粒细胞减少症"的创新药。 此次海外市场的首批发货，将为未来境外其他市场顺利发货提供宝贵经验。 ...